PHF6 maintains acute myeloid leukemia via regulating NF-κB signaling pathway

[1]  Xiaoming Wang,et al.  PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression , 2021, Leukemia.

[2]  O. Weinberg,et al.  PHF6 Mutations in Hematologic Malignancies , 2021, Frontiers in Oncology.

[3]  H. Kantarjian,et al.  Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach , 2021, Cancer.

[4]  E. Passegué,et al.  Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis , 2020, Nature Reviews Cancer.

[5]  Joanna Zawitkowska,et al.  Microarray testing as an efficient tool to redefine hyperdiploid paediatric B-cell precursor acute lymphoblastic leukaemia patients. , 2019, Leukemia research.

[6]  A. Iwama,et al.  The chromatin-binding protein Phf6 restricts the self-renewal of hematopoietic stem cells. , 2019, Blood.

[7]  J. Gécz,et al.  PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia. , 2019, Blood.

[8]  Bruno Paulino Di Muzio,et al.  Acute myeloid leukaemia , 2019, Radiopaedia.org.

[9]  M. Loh,et al.  Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. , 2018, Cancer discovery.

[10]  Elli Papaemmanuil,et al.  PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. , 2018, Blood advances.

[11]  Steven J. M. Jones,et al.  The genetic basis and cell of origin of mixed phenotype acute leukaemia , 2018, Nature.

[12]  Saijuan Chen,et al.  Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1-dependent manner. , 2017, Blood.

[13]  Jason D. Buenrostro,et al.  PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes , 2017, Genes & development.

[14]  M. Fornerod,et al.  PHF6 mutations in paediatric acute myeloid leukaemia , 2016, British journal of haematology.

[15]  S. Miyano,et al.  Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms , 2016, Leukemia.

[16]  Basharut A. Syed,et al.  Acute myeloid leukaemia drugs market , 2016, Nature reviews. Drug discovery.

[17]  W. Hiddemann,et al.  MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML. , 2016, Cell reports.

[18]  E. Vellenga,et al.  Constitutive NF-κB activation in AML: Causes and treatment strategies. , 2016, Critical reviews in oncology/hematology.

[19]  Boris Lenhard,et al.  Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia , 2016, Cancer cell.

[20]  D. Picketts,et al.  PHF6 Degrees of Separation: The Multifaceted Roles of a Chromatin Adaptor Protein , 2015, Genes.

[21]  B. Klaholz,et al.  Structure and function insights into the NuRD chromatin remodeling complex , 2015, Cellular and Molecular Life Sciences.

[22]  Brian A. Joughin,et al.  A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth , 2015, Genes & development.

[23]  C. Bloomfield,et al.  Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Mrózek,et al.  Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. , 2011, Hematology/oncology clinics of North America.

[25]  Lars Bullinger,et al.  MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. , 2011, Cancer cell.

[26]  Yonghong Xiao,et al.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. , 2011, Cancer cell.

[27]  M. Esteller,et al.  Cancer epigenetics reaches mainstream oncology , 2011, Nature Medicine.

[28]  A. Hunter,et al.  T‐cell acute lymphoblastic leukemia in association with Börjeson–Forssman–Lehmann syndrome due to a mutation in PHF6 , 2010, Pediatric blood & cancer.

[29]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[30]  Rob Pieters,et al.  PHF6 mutations in T-cell acute lymphoblastic leukemia , 2010, Nature Genetics.

[31]  J. Kowalski,et al.  C/EBPα or C/EBPα oncoproteins regulate the intrinsic and extrinsic apoptotic pathways by direct interaction with NF-κB p50 bound to the bcl-2 and FLIP gene promoters , 2008, Leukemia.

[32]  M. Cleary,et al.  Protein arginine-methyltransferase-dependent oncogenesis , 2007, Nature Cell Biology.

[33]  G. Kroemer,et al.  Targeting NF-κB in hematologic malignancies , 2006, Cell Death and Differentiation.

[34]  W. Hiddemann,et al.  The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice. , 2005, The Journal of clinical investigation.

[35]  V. Imbert,et al.  Targeting NF-κB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells , 2005 .

[36]  M. Tomasson,et al.  An activated receptor tyrosine kinase, TEL/PDGFβR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Shaw,et al.  Mutations in PHF6 are associated with Börjeson–Forssman–Lehmann syndrome , 2002, Nature Genetics.

[38]  M. Weber,et al.  Increased IκB kinase activity is associated with activated NF-κB in acute myeloid blasts , 2002, Leukemia.

[39]  K. Dawood,et al.  Expression profiling of some Acute Myeloid Leukemia - associated markers to assess their diagnostic / prognostic potential. , 2021, Genetics and molecular biology.

[40]  Z. Ju,et al.  Rheb1 promotes tumor progression through mTORC1 in MLL-AF9-initiated murine acute myeloid leukemia , 2016 .

[41]  S. Gutiérrez,et al.  Epigenetic changes: a common theme in acute myelogenous leukemogenesis , 2013, Journal of Hematology & Oncology.

[42]  A. Ferrando,et al.  PHF6 mutations in adult acute myeloid leukemia , 2011, Leukemia.

[43]  G. Kroemer,et al.  Targeting NF-kappaB in hematologic malignancies. , 2006, Cell death and differentiation.

[44]  V. Imbert,et al.  Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. , 2005, Blood.

[45]  M. Weber,et al.  Increased IkappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. , 2002, Leukemia.